{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:43:25Z","timestamp":1778237005654,"version":"3.51.4"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T00:00:00Z","timestamp":1379635200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0075252","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T20:52:58Z","timestamp":1379710378000},"page":"e75252","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs"],"prefix":"10.1371","volume":"8","author":[{"given":"Min","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakhle","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Auld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,9,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"N Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"M Hallek","year":"2008","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"WG Wierda","year":"2007","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"LZ Rassenti","year":"2008","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"JG Gribben","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11899-011-0110-1","article-title":"Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?","volume":"7","author":"L Sellner","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrclinonc.2010.101","article-title":"Chemoimmunotherapy of chronic lymphocytic leukemia","volume":"7","author":"CS Tam","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","first-page":"457","article-title":"Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia","volume":"30","author":"MR Grever","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"MJ Keating","year":"1989","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"JC Byrd","year":"2003","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"MJ Keating","year":"2002","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"M Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"CS Tam","year":"2008","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2146\/ajhp060371","article-title":"Pregabalin: An antiepileptic agent useful for neuropathic pain","volume":"64","author":"ML Blommel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"ref15","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"PJ Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ncprheum0906","article-title":"Is pregabalin a safe and effective treatment for patients with fibromyalgia?","volume":"4","author":"M Spaeth","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of \u03b2-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"RV Lacro","year":"2007","journal-title":"Am Heart J"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a Primary Target of Thalidomide Teratogenicity","volume":"12","author":"T Ito","year":"2010","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1517\/14656566.1.4.849","article-title":"Thalidomide: a remarkable comeback","volume":"1","author":"JM Jacobson","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics","volume":"3","author":"R Huang","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"A Wiestner","year":"2003","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.0604348103","article-title":"Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries","volume":"103","author":"J Inglese","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/adt.2006.053","article-title":"Bioluminescent assays for high-throughput screening","volume":"5","author":"F Fan","year":"2007","journal-title":"Assay Drug Dev Technol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/227168a0","article-title":"Characteristics of a human diploid cell designated MRC-5","volume":"227","author":"JP Jacobs","year":"1970","journal-title":"Nature"},{"key":"ref25","first-page":"1390","article-title":"The vinca alkaloids: a new class of oncolytic agents","volume":"23","author":"IS Johnson","year":"1963","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18388\/abp.1998_4280","article-title":"The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations","volume":"45","author":"J Mazerski","year":"1998","journal-title":"Acta Biochim Pol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"KR Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"ref28","article-title":"Principles of Oncologic Pharmacotherapy","year":"2008"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/rheumatology\/36.5.560","article-title":"Auranofin","volume":"36","author":"WF Kean","year":"1997","journal-title":"Br J Rheumatol"},{"key":"ref30","first-page":"94","article-title":"Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase","volume":"41","author":"V Gandin","year":"1981","journal-title":"Biochem Pharmacol"},{"key":"ref31","first-page":"32","article-title":"Screening trial with the coordinated gold compound auranofin using mouse lymphocytic leukemia P388","volume":"45","author":"TM Simon","year":"1985","journal-title":"Cancer Res"},{"key":"ref32","article-title":"Treatment with auranofin induces oxidative and lethal endoplasmic reticulum (ER) stress exerting single agent activity against primary CLL cells","author":"R Rao","year":"2011","journal-title":"Blood"},{"key":"ref33","article-title":"The gold compound auranofin induces oxidative stress and apoptosis in primary CLL cells independent of classic prognostic markers and the protective effect of the tissue microenvironment","author":"N Saba","year":"2012","journal-title":"Blood"},{"key":"ref34"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"G Egger","year":"2004","journal-title":"Nature"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"EJ Derissen","year":"2013","journal-title":"Oncologist"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd1698","article-title":"Azacitidine","volume":"4","author":"JP Issa","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","article-title":"5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia","volume":"85","author":"DD Von Hoff","year":"1976","journal-title":"Ann Intern Med"},{"key":"ref39"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clml.2012.11.009","article-title":"Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: A phase II study","volume":"13","author":"A Malik","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1067\/mem.2003.72","article-title":"British anti-Lewisite (dimercaprol): an amazing history","volume":"41","author":"JA Vilensky","year":"2003","journal-title":"Ann Emerg Med"},{"key":"ref42"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJM195112132452401","article-title":"The effect of bal (2,3-dimercaptopropanol) on hepatolenticular degeneration (wilson's disease)","volume":"245","author":"D Denny-Drown","year":"1951","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/096032719701600807","article-title":"Are we ready to replace dimercaprol (BAL) as an arsenic antidote?","volume":"16","author":"H M\u00fcckter","year":"1997","journal-title":"Hum Exp Toxicol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/092986709787002682","article-title":"A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007","volume":"16","author":"H Xu","year":"2009","journal-title":"Curr Med Chem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2174\/1381612053764724","article-title":"Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents","volume":"11","author":"Y You","year":"2005","journal-title":"Curr Pharm Des"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0031-9422(00)00094-7","article-title":"Podophyllotoxin","volume":"54","author":"C Canel","year":"2000","journal-title":"Phytochemistry"},{"key":"ref48","first-page":"36","article-title":"Mithramycin inhibition of ribonucleic acid synthesis","volume":"26","author":"JW Yarbro","year":"1968","journal-title":"Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mpo.2950240511","article-title":"Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin)","volume":"24","author":"BJ Kennedy","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00689589","article-title":"Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia","volume":"25","author":"E Archimbaud","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0145-2126(96)00108-7","article-title":"A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia","volume":"21","author":"JP Dutcher","year":"1997","journal-title":"Leuk Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","article-title":"Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia","volume":"103","author":"O Tournilhac","year":"2004","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-07-1371","article-title":"Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication","volume":"14","author":"F Bosch","year":"2008","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1371\/annotation\/e2536fcb-3ab3-44a0-8eab-91aaeb8e49b6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0075252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T13:36:56Z","timestamp":1596548216000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0075252"}},"subtitle":[],"editor":[{"given":"Chandra","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,20]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0075252","relation":{"correction":[{"id-type":"doi","id":"10.1371\/annotation\/e2536fcb-3ab3-44a0-8eab-91aaeb8e49b6","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,20]]}}}